Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 9/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 8/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.66 |
| ▸ | PDE4A | P27815 | 3/20 | 0.66 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.66 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.66 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL380135 | 0.80 | ADORA2A (1.00) | ADORA2BADORA3ADORA2APDE4APDE4B | |
| SCHEMBL5515444 | 0.80 | ADORA2A (0.71) | ADORA2BADORA3ADORA2APDE4APDE4B | |
| SCHEMBL30012331 | 0.79 | ADORA2B (0.65) | ADORA2BADORA3ADORA2APDE4APDE4B | |
| SCHEMBL7217322 | 0.78 | ADORA2A (0.97) | ADORA2BADORA3ADORA2APDE4APDE4B | |
| SCHEMBL4423680 | 0.77 | ADORA2B (1.00) | ADORA2BADORA3ADORA2APDE4APDE4B | |
| SCHEMBL4602969 | 0.77 | ADORA2B (0.73) | ADORA2BADORA3ADORA2APDE4APDE4B | |
| SCHEMBL7491460 | 0.77 | ADORA2B (0.70) | ADORA2BADORA3ADORA2APDE4APDE4B | |
| SCHEMBL2541187 | 0.76 | ADORA2B (0.61) | ADORA2BADORA3ADORA2APDE4APDE4B | |
| SCHEMBL6464355 | 0.76 | ADORA2B (1.00) | ADORA2BADORA3ADORA2APDE4APDE4B | |
| SCHEMBL9386893 | 0.76 | ADORA2A (0.70) | ADORA2BADORA3ADORA2APDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101690744-A | synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines | METAPROTEOMICS LLC | 2010-04-07 | — | — | CN | claimed |
| CN-1946409-A | Synergistic anti-inflammatory pharmaceutical compositions and related methods of using curcuminoids or methylxanthines | METAPROTEOMICS LLC (US) | 2007-04-11 | — | — | CN | claimed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| CN-110573509-B | MLKL inhibitors | 北京生命科学研究所 | 2023-05-26 | — | — | CN | disclosed |
| WO-2023039578-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | OMEROS CORPORATION (US) | 2023-03-16 | — | — | WO | disclosed |
| US-20170050173-A1 | PROGRAMMABLE MIP CATCH AND RELEASE TECHNOLOGY | THE DECAF COMPANY, LLC (US) | 2017-02-23 | — | — | US | disclosed |
| US-20170050175-A1 | PROGRAMMABLE MIP CATCH AND RELEASE TECHNOLOGY | THE DECAF COMPANY, LLC | 2017-02-23 | — | — | US | disclosed |
| US-20170050174-A1 | PROGRAMMABLE MIP CATCH AND RELEASE TECHNOLOGY | STUCKEY, MARION MELVIN | 2017-02-23 | — | — | US | disclosed |
| WO-2013058681-A2 | SUBSTITUTED PHENOXYACETIC ACIDS AND ESTERS AND AMIDES THEREOF, COMPRISING A 2,6-DIOXO-2,3,6,7-TETRAHYDRO-1Н-PURINE-8-YL FRAGMENT AND CONSTITUTING А2A ADENOSINE RECEPTOR ANTAGONISTS, AND THE USE THEREOF | ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НЬЮВАК" (ООО "НЬЮВАК") (RU) | 2013-04-25 | — | — | WO | disclosed |
| WO-2010065959-A1 | METHOD OF PREPARING ADENOSINE-RESISTANT ANTI-TUMOR T LYMPHOCYTES FOR ADOPTIVE IMMUNOTHERAPY | NORTHEASTERN UNIVERSITY (US) | 2010-06-10 | — | — | WO | disclosed |
| CN-101690744-A | synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines | METAPROTEOMICS LLC | 2010-04-07 | — | — | CN | disclosed |
| CN-1946409-A | Synergistic anti-inflammatory pharmaceutical compositions and related methods of using curcuminoids or methylxanthines | METAPROTEOMICS LLC (US) | 2007-04-11 | — | — | CN | disclosed |
| US-6710051-B1 | SUBSTANCES IS A XANTHINE AND IS ADMINISTERED IN A DOSAGE OF 7.5-750 MG 1-4 TIMES DAILY TO TREAT MYOPIA | KLAUS TRIER APS (DK) | 2004-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170050175-A1 | PROGRAMMABLE MIP CATCH AND RELEASE TECHNOLOGY | CCL11, CXCL10, CCL5 | ADORA2B 2584/4885ADORA3 1941/4885ADORA2A 2500/4885 |
| US-20170050173-A1 | PROGRAMMABLE MIP CATCH AND RELEASE TECHNOLOGY | CCL11, CXCL10, CCL5 | ADORA2B 2584/4885ADORA3 1941/4885ADORA2A 2500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.